Table 1 Baseline characteristics of the hospitalized AF patients per DOAC. IQR= interquartile range; BMI= body mass index; SSRIs= selective serotonine reuptake inhibitors.
Characteristics
RIVAROXABAN (n=402) DABIGATRAN (n=148) EDOXABAN (n=552) APIXABAN (n=586)
p-value
Age (years), median (IQR) 77.0 (70.0-84.3) 76.0 (68.0-84.0) 72.0 (60.0-82.0) 81.0 (72.0-87.0) <0.01
Male gender, n (%) 240 (59.7) 85 (57.4) 316 (57.2) 285 (48.6) <0.01
Weight (kg), median (IQR) <60 kg, n (%) 78.9 (67.0-90.0) 48 (11.9) 79.0 (67.0-90.0) 18 (12.2) 77.0 (65.0-89.3) 78 (14.1) 70.1 (59.5-85.0) 147 (25.1) <0.01 <0.01
BMI (kg/m2), median (IQR) BMI <18 kg/m2, n (%) BMI >30 kg/m2, n (%) 27.3 (24.0-31.0) 8 (2.0) 116 (28.9) 27.0 (24.2-30.9) 1 (0.7) 43 (29.1) 26.6 (23.0-30.1) 17 (3.1) 135 (24.5) 25.4 (22.0-29.7) 28 (4.8) 127 (21.7) <0.01 0.02 0.04
Residential care center, n (%) 40 (10.0) 20 (13.5) 42 (7.6) 91 (15.5) <0.01
Preadmission medication, n (%) 328 (81.6) 127 (85.8) 295 (53.4) 410 (70.0)
Surgery during hospital stay, n (%) 159 (39.6) 54 (36.5) 255 (46.2) 156 (26.6) <0.01
Bioprosthetic heart valve n, (%) 31 (7.7) 4 (2.7) 23 (4.2) 31 (5.3) 0.04
Renal function (mL/min), median (IQR) <30 mL/min, n (%) 30-49 mL/min, n (%) ≥50 mL/min, n (%) Missing, n (%) 67.0 (48.0-88.0) 25 (6.2) 82 (20.4) 291 (72.4) 4 (1.0) 69.0 (51.5-91.5) 6 (4.1) 26 (17.6) 113 (76.4) 3 (2.0) 76.0 (53.0-104.0) 22 (4.0) 83 (15.0) 442 (80.1) 5 (0.9) 52.0 (36.0-74.0) 86 (14.7) 189 (32.3) 307 (52.4) 4 (0.7) <0.01 <0.01 <0.01 <0.01
Co-morbidities n, (%) Hypertension Diabetes Heart failure Cancer 280 (69.7) 112 (27.9) 112 (27.9) 45 (11.2) 105 (70.9) 36 (24.3) 42 (28.4) 8 (5.4) 352 (63.8) 113 (20.5) 122 (22.1) 42 (7.6) 428 (73.0) 153 (26.1) 208 (35.5) 68 (11.6) <0.01 0.04 <0.01 0.03
Co-medication n, (%) Lipid lowering Levothyroxine Gastrointestinal Narcotic analgesics Benzodiazepines SSRIs 172 (42.8) 60 (14.9) 195 (48.5) 103 (25.6) 104 (25.9) 31 (7.7) 83 (56.1) 18 (12.2) 71 (48.0) 43 (29.1) 37 (25.0) 20 (13.5) 225 (40.8) 53 (9.6) 212 (38.4) 91 (16.5) 119 (21.6) 40 (7.2) 244 (41.6) 97 (16.6) 294 (50.2) 104 (17.7) 148 (25.3) 60 (10.2) <0.01 <0.01 <0.01 <0.01 0.42 0.06
Concomitant use of antiplatelets n, (%) Aspirin Clopidogrel Ticagrelor Aspirin + clopidogrel Aspirin + ticagrelor 95 (23.6) 72 (17.9) 15 (3.7) / 6 (1.5) 2 (0.5) 18 (12.2) 12 (8.1) 4 (2.7) 1 (0.7) 1 (0.7) / 86 (15.6) 66 (12.0) 14 (2.5) / 6 (1.1) / 128 (21.8) 78 (13.3) 30 (5.1) 1 (0.2) 19 (3.2) /
<0.01
Thrombocytopenia n, (%) 57 (14.2) 25 (16.9) 60 (10.9) 97 (16.6) 0.04
Anaemia n, (%) 198 (49.3) 61 (41.2) 172 (31.2) 277 (47.3) <0.01
History of bleeding n, (%) 56 (13.9) 14 (9.5) 58 (10.5) 100 (17.1) <0.01
CHA2DS2-VASc, median (IQR) 4 (3-5) 4 (3-5) 3 (2-5) 4 (3-5) <0.01
HASBLED, median (IQR) 2 (1-3) 2 (2-3) 2 (1-3) 2 (2-3) <0.01